LOS ANGELES--(BUSINESS WIRE)--Dec. 14, 2005--Cougar Biotechnology, Inc., a privately held biotechnology company, today announced that the first patient has been enrolled in the Phase I/II trial of the Company’s drug CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced prostate cancer. The Phase I/II trial is being conducted at The Institute of Cancer Research, in the Cancer Research UK Centre for Cancer Therapeutics, and at The Royal Marsden Hospital in the United Kingdom.
